1. Opening Hook
Torrent Pharma just walked into Q2 FY26 like a chronic therapy boss at a generic party.
While half the industry was blaming GST, supply chains, or planetary alignment, Torrent calmly said, “Minimal impact, next question.”
India kept chugging, Brazil sprinted, the US finally woke up, and Germany… well, Germany is still waiting for its supplier to get their act together.
Management sounded confident, numbers mostly backed them, and semaglutide made its mandatory cameo like a Bollywood item song.
Margins stayed steady, leverage shrank, and acquisitions moved one regulatory checkbox closer to reality.
But before you start chanting “compounder stock,” remember: Germany is shaky, US is still rebuilding, and sema approvals are more hope than timeline.
Read on — the fun stuff hides between confidence and caveats.
2. At a Glance
- Revenue up 14% – Growth broad-based, not a one-country wonder.
- EBITDA up 15% – Margins held at 32.8%, discipline > drama.
- India up 12% – Chronic therapies doing chronic overperformance things.
- Brazil up 21% (13% CC) – Branded generics partying hard.
- US up 26% – After years of silence, the engine coughed back to life.
- Germany down 5% (CC) – Supplier issues still writing the script.
- Net debt/EBITDA at 0.45x – Balance sheet now officially boring (good thing).
3. Management’s Key Commentary
“Branded markets accounted for 73% of overall revenue this quarter.”
(Translation: Generics are fine, but brands pay the bills 😏)
“India grew at 12% versus IPM growth of 8%.”
(Translation: We ran while the market jogged)
“Brazil constant currency growth was 13%.”
(Translation: Ignore forex noise, the business is solid)
“US revenues grew 26% driven by new launches.”
(Translation: The launch engine is sputtering back to life 🚗)
“Germany declined due to third-party supplier disruption.”
(Translation: Not our fault, but still our headache)
“Net debt to EBITDA now stands at 0.45x.”
(Translation: Balance sheet now sleeps peacefully)
“Semaglutide could be a material opportunity at 10–15%
